Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the eligibility requirements for patients included in the phase 2 trial results that led to the FDA approval of infigratinib.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the adverse events experienced by patients during the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes.
Factors that may have contributed to the screening declines include site closures and temporary pausing of services.
Although researchers identified 3 agents that increased the risk of herpes zoster among patients with psoriasis, they also found 2 therapies that seemed to decrease the risk.
The current study analyzed human tumor samples from 6 cancer types: liver, melanoma, colorectal, non-small lung, head and neck, and breast cancer.
Debate and discussion about the origin of the virus that causes COVID-19 have been at the forefront of global consciousness since the first cases were reported in December 2019.
Sacituzumab govitecan is approved for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 more prior systemic therapies.
The clinical benefit rate was observed in 16.7% of patients in the balixafortide arm and in 19.6% of patients in the eribulin monotherapy arm.
Upadacitinib (RINVOQ; AbbVie), 15 mg or 30 mg and once daily, met the primary endpoint of clinical remission and all secondary endpoints at week 52 in a phase 3 ulcerative colitis study.
Greater risk for heart damaged come from coronavirus infection, and patients should not be discouraged from vaccination.
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide injection in adults with type 2 diabetes was conducted.
OBRA '90 reinforces a culture of "give the service away and focus on preserving the buy-sell margin of the product."
Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the findings of the phase 2 trial assessing infigratinib for treatment of previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze; Jazz Pharmaceuticals) provides a new alternative for a therapy in long-standing global shortage.
Lactitol (Pizensy) is an oral solution for treating chronic idiopathic constipation in adults.
Study to evaluate the safety and efficacy of talazoparib, an oral PARP inhibitor, in combination with enzalutamide, an androgen receptor inhibitor.
The fully human monoclonal antibody is currently approved in more than 60 countries.
Kirollos Hanna, PharmD, BCPS, BCOP, assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview - Maple Grove, discusses the potential impact of ACCC's Multiple Myeloma Dispensing Project on the field.
Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.
The COVID-19 pandemic has led to significant innovation, which presents a unique opportunity for pharmacists to advance pharmacy practice by serving as the integral drug monitoring experts of the health care team.
In a national survey, pharmacists reported on the extent to which various services were provided.
The research concluded that eating starchy snacks after meals and eating a Western-style lunch containing refined grains, cheese, and cured meat elevates the risk of dying from heart disease and other illnesses.
Researchers found an overall response rate of 29.8% in patients treated with 177Lu-PSMA-617, compared to a 1.7% partial response in the standard of care only arm.
The investigators found that population-based cancer registries showed a 10.2% decline in real-time electronic pathology reports in 2020 compared to 2019.
Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.
Umbralisib was granted accelerated approval by the FDA for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.
Edwin Gump, PhD, vice president of the Small Molecules Department at US Pharmacopeia (USP), discusses USP’s reference standards that support the analysis and monitoring of nitrosamine impurities in the drug supply chain.
Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.
